CoChat

Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance

Open access
Schrank, Zachary, Chhabra, Gagan, Lin, Leo, Iderzorig, Tsatsral, Osude, Chike, Khan, Nabiha, Kuckovic, Adijan, Singh, Sanjana, Miller, Rachel, Puri, Neelu · 2018 · Cancers
Cited by 143

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Lung cancer is treated with many conventional therapies, such as surgery, radiation, and chemotherapy. However, these therapies have multiple undesirable side effects. To bypass the side effects elicited by these conventional treatments, molecularly-targeted therapies are currently in use or under development. Current molecularly-targeted therapies effectively target specific biomarkers, which are commonly overexpressed in lung cancers and can cause increased tumorigenicity. Unfortunately, several molecularly-targeted therapies are associated with initial dramatic responses followed by acquired resistance due to spontaneous mutations or activation of signaling pathways. Acquired resistance to molecularly targeted therapies presents a major clinical challenge in the treatment of lung cancer. Therefore, to address this clinical challenge and to improve lung cancer patient prognosis, we need to understand the mechanism of acquired resistance to current therapies and develop additional novel therapies. This review concentrates on various lung cancer biomarkers, including EGFR, ALK, and BRAF, as well as their potential mechanisms of drug resistance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers10070224

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 143

Metadata

Authors
Schrank, Z., Chhabra, G., Lin, L., Iderzorig, T., Osude, C., Khan, N., Kuckovic, A., Singh, S., Miller, R., & Puri, N.
Venue
Cancers
Publisher
MDPI AG
Published
2018-07-04
Volume
10
Issue
7
Pages
224
ISSN
2072-6694 (ISSN-L)
OpenAlex
W2810788886
Cited by
143
References
16
FWCI
12.01
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance. https://app.cochat.ai/papers/10.3390/cancers10070224
The paper
Schrank, Z., Chhabra, G., Lin, L., Iderzorig, T., Osude, C., Khan, N., Kuckovic, A., Singh, S., Miller, R., & Puri, N. (2018). Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance. Cancers. https://doi.org/10.3390/cancers10070224

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.